期刊文献+

UPLC-MS-MS法测定原料药中对甲苯磺酸酯类遗传毒性杂质 被引量:1

Determination of P-toluenesulfonic Acid Esters Impurities in API by UPLC-MS/MS
下载PDF
导出
摘要 建立超高效液相色谱-串联质谱法(UPLC-MS/MS)测定硫酸氢氯吡格雷中对甲苯磺酸甲酯和对甲苯磺酸乙酯。以0.1%甲酸水-乙腈为流动相进行线性梯度洗脱。采用ESI离子源正离子模式,多反应监测模式下以外标法对2种遗传毒性杂质进行定量测定。2种遗传毒性杂质质量浓度在5.0~200.0 ng·mL^-1范围内线性关系良好;低中高加标回收率(n=3)为94.1%~105.3%,RSD为1.7%~4.4%。本方法操作简便,结果可靠,可用于硫酸氢氯吡格雷中对甲苯磺酸酯类遗传毒性杂质的检测。 An UPLC-MS/MS analytical method for the determination of genotoxic impurities(methyl p-toluenesulfonate and ethyl p-toluenesulfonate)in clopidogrel bisulfate was established.The separation was performed with the mobile phase consisting of 0.1%formic acid aqueous solution and acetonitrile.Multiple reaction monitoring(MRM)was performed on a triple quadrupole mass spectrometer equipped with a ESI source in the positive mode.The calibration curve was linear for other compounds in the range of 5.0~200.0 ng·mL^-1.The recoveries(n=3)of adding concentrations were 94.1%~105.3%,RSD were 1.7%~4.4%.The established method is simple,rapid and reliable,which is applicable for both quantification of two genotoxic impurities in in clopidogrel bisulfate.
作者 勾新磊 徐双双 赵婷 张梅 刘伟丽 高峡 赵新颖 胡光辉 GOU Xin-lei;XU Shuang-shuang;ZHAO Ting;ZHANG Mei;LIU Wei-li;GAO Xia;ZHAO Xin-ying;HU Guang-hui(Beijing Key Laboralory of Organic Materials Testing Technology&Quality Evaluation,Beijing Centre for Physical and Chemical Analysis,Beijing 100089,China)
出处 《广州化工》 CAS 2020年第21期109-110,138,共3页 GuangZhou Chemical Industry
基金 改革与发展专项(2020ZL0304)。
关键词 超高效液相色谱-串联质谱 遗传毒性杂质 对甲苯磺酸甲酯 对甲苯磺酸乙酯 UPLC-MS/MS genotoxic impurity methyl p-toluenesulfonate ethyl p-toluenesulfonate
  • 相关文献

参考文献6

二级参考文献60

  • 1梁美好,沈正荣.(+)-氯吡格雷的合成工艺改进[J].中国药物化学杂志,2007,17(3):163-165. 被引量:12
  • 2JIAJS.Clopidgrel clinical observation of15cases of nephrotic syndrome .工企医刊,2008,21(3):28-28.
  • 3SHOUML PANDL.Losartan and clopidgrelin the treatment of early diabetic naphropathy .中国中西医结合肾病杂志,2007,3(8):167-168.
  • 4ZHANGYH.Refractory nephrotic syndrome efficacy of anticoag-ulation therapy .中国中西医结合肾病杂志,2007,3(8):167-168.
  • 5LIJ XIAOH LIYF.Ticlopidine in the treatment of primary nephrotic syndrome .云南医药,2001,22(1):26-27.
  • 6GIBSON C M, DUMAINE R L, GELFAND E V, et al. The TI- MI study group. Association of glomerular filtration rate on pres- entation with subsequent mortality in non-ST-segment elevation a- cute coronary syndrome, observations in 13 307 patients in five TIMI trials[J]. Eur Heart J, 2004, 25(22) :1998-2005.
  • 7JANUZZI J L, SNAPINN S M, DIBATFISTE P M, et al. Bene- fits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Results from the plate- let receptor inhibition in ischemic syndrome management in pa- tients limited by unstable signs and symptoms ( PRISM-PLUS ) trial[ J]. Circulation, 2002, 105 (20) :2361-2367.
  • 8WRIGHT R S, REEDER G S, HERZOG C A, et al. Acute My- ocardial infarction and renal dysfunction: a high-risk combination [J~. Ann Intern Med, 2002, 137(7) :563-570.
  • 9The CURE Investigators. The Clopidogrel in Unstable angina to Prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta analysis of the effects of thienopyridines in vascular disease [ J ]. Eur Heart J, 2000, 21 (24) :2033-2041.
  • 10The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of Clopidogrel in Addition to Aspirin in patients with ST elevation. Acute coronary syndromes without ST-segment elevation[J]. N Engl J Med, 2001, 345(20) :494- 502.

共引文献27

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部